Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researcher: Controversial Stop-Smoking Drug Champix is Safe

By Drug Discovery Trends Editor | June 1, 2015

The controversial smoking cessation drug Champix has been linked to suicidal side-effects but, according to a leading Adelaide respiratory researcher, Champix is safe and can improve someone’s chances of kicking the habit. 

Speaking in the lead up to World No Tobacco Day (Sunday 31 May), Kristin Carson encourages the use of Champix (or Varenicline Tartrate) for smokers admitted into hospital with a smoking-related illness.

“Smoking accounts for 15 percent of all deaths, 80 percent of all lung cancers and is responsible for the greatest disease burden in Australia,” said Ms Carson, from The Queen Elizabeth Hospital (Basil Hetzel Institute for Translational Health Research), who has recently completed PhD research into quitting smoking at the University of Adelaide’s School of Medicine. 

“Champix was made available to Australian smokers in 2008 and has a dual effect – it eases cravings and reduces the ‘pleasure’ of smoking. However, American studies in 2007 linked Champix to nasty side effects like thoughts of suicide, suicidal behavior, erratic behavior and drowsiness. 

“In our Adelaide-based study, we found that people who took Champix in conjunction with attending counseling had better control over their cravings and had lower levels of anxiety while quitting, compared to patients who only attended counseling. And, after the 12-week program, 31 percent of the patients on Champix had quit smoking compared to 21 percent of the patients who attended counselling only,” she said. 

Ms Carson said in the study she led, no one experienced suicidal thoughts but there were some side-effects. 

“The patients on Champix experienced higher levels of nausea, abnormal dreams, headaches and insomnia than those who didn’t take the drug. However, most of these side effects were only experienced by a small number of patients and no one reported having suicidal thoughts,” said Ms Carson. 

“It’s important that those who are quitting smoking, particularly when they are using medication like Champix, also use counselling. A counsellor, such as those available via Quit SA on the phone, can monitor the patient’s symptoms and any side effects, and consulting with a counsellor improves the chances of successfully quitting,” she said. 

Ms Carson said smokers looking to quit should weigh up their options and choose a method that’s best for them. 

“There are lots of options for people who want to quit smoking and the best place to start is cancersa.org.au/quitline. However, for those who are finding it particularly hard to quit, Champix should be considered,” said Ms Carson. 

This research was published in the journals Nicotine and Tobacco Research and Thorax, and was funded by the Department of Respiratory Medicine at The Queen Elizabeth Hospital

Source: University of Adelaide


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE